10 Jan

What to Expect from Roche’s Tecentriq and Avastin in 2018

WRITTEN BY Daniel Collins

Tecentriq and Avastin revenue trends

In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.7 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively. In 1Q17, 2Q17, and 3Q17, Tecentriq generated revenues of 115 million Swiss francs, 121 million Swiss francs, and 128 million Swiss francs, respectively.

What to Expect from Roche’s Tecentriq and Avastin in 2018

IMmotion 151 trial

In December 2018, Roche announced results from the phase three IMmotion 151 trial. In the IMmotion 151 trial, Tecentriq and Avastin combination therapy met the co-primary endpoint of progression-free survival compared to sunitinib.

Roche conducted the phase three IMmotion 151 trial to evaluate the safety and efficacy of Tecentriq and Avastin combination therapy compared to sunitinib for the treatment of individuals with locally advanced or metastatic renal cell carcinoma who have not previously received systemic therapy.

In the IMmotion 151 trial, Tecentriq and Avastin demonstrated a statistically significant and clinically meaningful decrease in the risk of disease worsening or death (progression-free survival) in individuals with advanced or metastatic renal cell carcinoma whose tumors expressed PD-L1 (programmed death-ligand 1) protein compared to sunitinib as a first-line treatment.

The results of the clinical trial will be discussed with health authorities including the European Medicines Agency and the US Food and Drug Administration (or FDA).

About Tecentriq and Avastin

Tecentriq is indicated for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-containing chemotherapy or showed disease progression during or after any platinum-containing chemotherapy. Tecentriq is also indicated for the treatment of individuals with metastatic non-small cell lung cancer who showed disease progression during or after platinum-containing chemotherapy. Avastin is indicated for metastatic colorectal cancer.

Tecentriq’s peers include Pfizer’s (PFE) Bavencio, Bristol-Myers Squibb’s (BMY) Opdivo, and Merck’s (MRK) Keytruda. The revenue growth of Roche’s Avastin and Tecentriq could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up about ~0.69% of VEU’s total portfolio holdings.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.